International Association for the Study of Lung Cancer: Results From the FURTHER Trial Demonstrate Firmonertinib is a Promising Potential Therapy for Patients With NSCLC With EGFR PACC Mutations
September 10, 2024
September 10, 2024
AURORA, Colorado, Sept. 10 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release:
(San Diego, Calif.--September 9, 2024, 10:05 a.m.) -- The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS antitumor activity, according to research presented today at the International Association for t . . .
(San Diego, Calif.--September 9, 2024, 10:05 a.m.) -- The tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung cancer across a broad range of EGFR PACC mutations in the first-line metastatic setting with CNS antitumor activity, according to research presented today at the International Association for t . . .